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I. INTRODUCTION
How should the UK address the increasing demand for human gametes-sperm and eggsfor use in medical treatment and research? At present, many patients remain childless while waiting for infertility treatment using donated gametes 1 and researchers claim that shortages, principally of human eggs, are hindering scientific progress and potential new treatments.
2 A review of fertility clinics by the Human Fertilisation and Embryology Authority (HFEA) reported that half were unable to meet demand for treatment with donor sperm and 90% were unable to meet demand for treatment with donor eggs. 3 Despite the development of alternatives to donated gametes, 4 availability thus continues to fall below demand. Similarly, the increasing 5 shortage of human eggs has led to researchers not pursuing their preferred strategy. At one point, experiments were conducted involving the transfer of human material into animal eggs instead of human eggs. 6 It is frequently noted that some patients and researchers travel to other countries for access to donor gametes where there are different, often less rigorous, regulatory controls. 7 In contrast to the national system applying to the donation of blood and organs for treatment, there is no centralised network addressing the need for gametes in treatment and research. The HFEA was established by the Human Fertilisation and Embryology Act 1990 (the 1990 Act) to license fertility treatment and research conducted using human gametes, but was not tasked with responsibility for ensuring the supply of donors. Since the government is currently in the process of restructuring the NHS and regulatory bodies addressing fertility, research and tissue-reforms which are to include the abolition of the HFEA in its current form by 2015
8 -now is a suitable time to reconsider the adequacy of the system for acquiring and allocating human gametes.
The absence of a body empowered to nationally coordinate the system of gamete donation means that approaches to the recruitment of gamete donors for treatment and research, and the allocation of donated gametes for treatment, vary between clinics. NHS Blood and Transplant (NHSBT) has responsibility for managing the national donation system for obtaining blood, tissues and organs for transplantation, 9 but has no responsibility for gametes. The idea of adopting such a system for gamete donation, at least for treatment, has widespread support. It has not, however, reached the stage whereby implementing legislation has even been proposed by the Government. In 1998, the HFEA expressed its support for the 'creation of a regional or national donor service', noting that the advantages of such a system would include facilitating donation, ensuring consistency in data collection, maximising the efficient use of the supply of donors and improved matching of patients from ethnic minority groups because of access to a wider pool of donated material. 10 The HFEA indicated that the biggest practical hurdle would be the start-up costs. In November 2008, a British Fertility Society (BFS) working party on sperm donation services in the UK expressed concern that 'a substantial majority of clinics are struggling to maintain sperm donation services and in some parts of the country these services have now ceased '. 11 It went on to recommend that the UK adopt a nationally co-ordinated approach to the organisation of sperm donation services, primarily to ensure 'economies of scale' in the costs and effort required to manage and maintain donors. 12 The Nuffield Council on Bioethics, which issued a report on the donation of bodily material for treatment and research in October 2011, similarly concluded that 'there should be a coherent managed infrastructure for egg and sperm donation, on the lines of the structures currently in place for organ donation'. 13 It argued that the state has a 'stewardship role' to play with regard to the donation of reproductive material-noting that the state has already accepted a role in regulating fertility treatment, has adopted guidance recommending publicly-funded IVF treatment and has a widely accepted role in protecting the welfare of children.
14 The Nuffield Council also noted that research, and its future potential benefits, is of 'vital public interest' 15 and the system for obtaining donations of organs and tissues from deceased persons for transplantation could be extended to encompass donation of organs and tissues for research. 16 This article will argue that the adoption of a national system of gamete donation for both treatment and research would have an additional advantage: it would facilitate the legal and ethical implementation of donor incentives. Three types of reward/incentive will be examined as potential mechanisms for prompting the donation of gametes from those who might not otherwise donate. While much can be said about the potential of a national donation system to facilitate the legal and ethical provision of financial incentives, it will be argued that such a system would be even better placed to enable the legal and ethical provision of non-financial incentives.
The analysis below will begin by briefly exploring the regulatory context, including the increasing need for human gametes and the limited restrictions imposed by the need to comply with the provisions of various European instruments. It will then explore the issues raised by the provision of financial incentives, before arguing that a national donation system would be well placed to ethically implement a form of exchange system in which donors would contribute to gain access, or alternatively an increased chance of access, to gametes. 18 and adopted additional means by which same sex couples can become the legal parents of a child born following assisted reproduction. 19 Secondly, regulation has required increased quality control standards to prevent the transmission of disease and ensure good success rates-such regulatory interventions include those connected to the implementation of the EU Tissues and Cells Directive (2004/23/EC)-and quality control standards have been shown to result in the rejection of the majority of prospective donors. 20 Thirdly, donor recruitment rates have been affected by legislative changes to anonymity. Children conceived using donor gametes after April 2005 have been granted the right to seek identifying information about the donor when they reach eighteen. 21 This has resulted in a drop in the number receiving treatment using donor gametes, 22 The profile of donors has also changed, with sperm donors now over twice as likely to be over 30 and already have children of their own. 25 Gametes are increasingly having to be sourced from abroad: about 20% of sperm donors and 2% of egg donors are from overseas, compared to 12% and 4%, respectively, in 2005'.
II. THE REGULATORY CONTEXT
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The last two decades have also seen additional demand for reproductive cells in research, supported by an expansion of the purposes for which embryo research is permitted by the 1990 Act. One reason for the increase in research uses for gametes is that it has become possible to extract stem cells from embryos 27 and embryonic stem cells are considered to have significant scientific and medical potential. All stems cells have the capacity to selfrenew and become other types of more specialist cells. Bone marrow transplants, for example, involve stem cells that have the capacity to regenerate and become three types of blood cells: white blood cells, red blood cells and platelets. What is special about embryonic stem cells is that they have the potential to become any of the 200 or so cell types in the human body (ie they are pluripotent). 28 The hope is that it will be possible to reprogramme such cells for use in the treatment of a wide range of diseases for which there is currently no cure, such as diabetes, Parkinson's disease and certain types of heart disease. 29 It is also possible to derive stem cells from cloned embryos produced by the method used to create Dolly the sheep. 30 This technique involves taking an egg, removing its nucleus (a tiny sac containing genetic material) and replacing it with the nucleus taken from a somatic cell (ie a normal body cell). In the case of Dolly, the replacement nucleus was taken from a mammary gland cell-Dolly the sheep was named after Dolly Parton. The resulting embryo is formed without the use of sperm and is virtually genetically identical to the individual providing the somatic cell nucleus. 31 Derived stem cells should therefore not be rejected by the body of the person from whose body the somatic cell is obtained, which could make them particularly useful for transplantation into the body of a sick patient. It is far too early to tell whether further research in this field will lead to the successful development of new forms of therapy. It should be noted that there is ongoing research into alternative sources of pluripotent stem cells, which do not necessitate the use of eggs or the destruction of embryos.
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The UK has a long history of embryo research and such practices are explicitly permitted by the 1990 Act under licence and subject to various conditions. 33 In particular, the research must be 'necessary or desirable' for one of the purposes listed by the Act. 34 There were initially five permitted purposes, but these were expanded in 2001 and then again in 2008 to the present eight. 35 As a result of amendments made by the 2008 Act, it is now clearer that the legislation permits embryo research intended to provide only scientific knowledge (ie basic, as opposed to applied research) and research into serious injuries not amounting to disease, such as spinal injuries. 36 The UK legislation also specifically permits the creation of embryos for research, as opposed to restricting research to embryos initially created for fertility treatment, and permits the creation of cloned embryos for research. 37 Few other countries have made this legislative move. 38 The creation of embryos for research is actually prohibited by Article 18(2) of the European Convention on Human Rights and Biomedicine (the Biomedicine Convention). This should not cause future problems for the UK, because if it were ever to sign and ratify the Biomedicine Convention, it could make a reservation to this provision under Article 36 on the basis that it has pre-existing legislation on the issue.
Together, the four regulatory developments outlined above have had a significant impact on gamete supply and demand for both treatment and research.
A. Incentives in the Current Regulatory Scheme
The 1990 Act empowered the HFEA to control the giving or receiving of 'money or other benefit' in respect of the supply of gametes by rendering such activities criminal unless authorised by Directions. 39 The HFEA has regularly reviewed compensation and incentives. Clinics were initially permitted to pay donors up to £15 per donation plus reasonable expenses.
40 Consultation in 1998 persuaded the HFEA not to remove this limited payment and it went on to permit rewarded egg-sharing in which a woman receives treatment at a reduced cost in exchange for donating some of her eggs. 41 Rewarded egg-sharing was subsequently extended to the donation of eggs for research in exchange for reduced IVF fees. 42 The reduction in cost of treatment is typically half or even the full cost of about £5,000 per cycle. 43 Sperm-sharing is permitted on equivalent terms. In 2006, following consultation on the pending implementation of the Tissues and Cells See, in particular, Sch 2, para 3A(1)(b) ('providing knowledge') and Sch 2, para3A(2)(a)-(b)) (which refers to 'other serious medical conditions'). Directive, 44 the HFEA removed the £15 direct payment and allowed only out-of-pocket expenses and a loss of earnings allowance capped at £250. In October 2011, after a further consultation, 45 the HFEA declared that it would take a more proactive approach to donor recruitment and retention in the period until its abolition. 46 It would allow those who donate gametes to receive a fixed sum for the expenses and inconveniences of donation: £750 per cycle for egg donors and £35 per visit for sperm donors. This level of compensation, which is expected to be implemented from mid-2012, is intended to provide financial recompense to ensure that donors do not lose out from donation 'without attracting those who are merely financially motivated'. 47 With regard to donation for research, it falls short of the Nuffield Council on Bioethics' recommendation for a pilot scheme of significant payments to women who donate eggs for research. 48 Thus, as things currently stand, the UK allows one form of incentive for gamete donation (rewarded gamete-sharing) and permits limited payment for the inconvenience of donation (which is intended to remove disincentives rather than incentivise donation).
Regulatory developments in the UK have taken place within an international context. There are three European instruments that seek to place restrictions on the offer of incentives for donation: the Biomedicine Convention of 1997, the EU Charter of Fundamental Rights of the European Union 2000 (the EU Charter), and the Tissues and Cells Directive.
Article 21 of Biomedicine Convention prohibits financial gain in the following terms: 'The human body and its parts shall not, as such, give rise to financial gain'. The Convention does not define body 'parts' or elaborate on the phrase 'as such'. The Explanatory Report states that Article 21 is to be interpreted as applying 'the principle of human dignity set forth in the preamble and in Article 1' and it includes blood, but not 'such products as hair and nails, which are discarded tissues, and the sale of which is not an affront to human dignity'. 49 We also routinely discard both sperm (following male masturbation or sex with a condom) and eggs (in menstruation cycles), but gametes have value extending beyond that of hair and nails, and their sale is generally considered to be at least as problematic as the sale of blood.
As already stated, the UK has neither signed nor ratified the Biomedicine Convention. Nonetheless, the more general European Convention on Human Rights and Fundamental Freedoms (EHRC) is often said to be a 'living instrument' 50 and it is increasingly being interpreted in the light of the Biomedicine Convention. In Glass v UK, the European Court of Human Rights cited the Biomedicine's provisions on consent (Articles 5-9) 51 and added that it did not consider UK law to be 'in any way inconsistent with the standards laid down' in the Biomedicine Convention in the area of consent'. 52 More recently, in MAK v UK, the Strasbourg Court again cited the provisions on consent and declared that UK domestic law 'fully accords' with the Biomedicine Convention. Strasbourg court cited the Biomedicine Convention's absence of a definition of 'everyone' in Article 1 in support of its interpretation of the Article 2 right to life of the ECHR. 55 France has signed the Convention but has yet to ratify it.
Interpreting the ECHR in the light of the Biomedicine Convention is only feasible where the relevant provision from the latter plausibly elaborates the former. Also, using the provisions of a non-binding instrument in this way can surely only be legitimate where there are additional reasons, beyond the provisions of the non-binding instrument, for accepting the relevant interpretation of the binding instrument. No provision in the EHRC plausibly requires its signatories to prohibit financial gain from body parts, although it is not difficult to interpret the EHRC as compatible with such a prohibition. Prohibiting persons from selling their gametes or services as a gamete donor would appear to engage the Article 8(1) right to private life, but Article 8(2) permits interference where it is in accordance with the law and is necessary for, inter alia, the protection of health or morals, or the protection of the rights and freedoms of others.
The Biomedicine Convention's prohibition is also incorporated into the EU Charter. Article 3 provides that the right to respect for a person's physical and mental integrity in 'medicine and biology' means 'in particular' that respect is to be given to 'the prohibition on making the human body and its parts as such a source of financial gain'. The Charter has been given legal force by the Lisbon Treaty, which came into effect on 1 December 2009. Under Article 6(1), the Charter is recognised by the EU as having 'the same legal value as the Treaties', although Article 51 states that the Charter does not extend the competence or powers of the EU. The UK, along with Poland, negotiated a protocol declaring that the Charter does not extend the jurisdiction of any Court within the EU or UK to find that any law, regulation, or administrative provision is inconsistent with the provisions of the Charter. 56 Thus, Article 3 cannot be considered to form part of English law. In any event, like the Biomedicine Convention, the EU Charter only prohibits making the body and its parts 'as such' a source of financial gain, the meaning of which will be considered presently.
The Tissues and Cells Directive has more direct legal relevance. 57 Article 12(1) requires Member States to 'endeavour to ensure voluntary and unpaid donations of tissues and cells'. It goes on to declare that donors may receive compensation 'which is strictly limited to making good the expenses and inconveniences related to the donation' and Member States may define the conditions under which such compensation is to be available. Article 12(2) requires Member States to 'endeavour to ensure that the procurement of tissues and cells as such is carried out on a non-profit basis'.
The Article 12 prohibition has a number of limitations. First, it uses the word 'endeavour' and thereby does not purport to lay down an absolute requirement. This flexibility permits Member States to meet demand by use of financial incentives. Second, while the Directive expressly applies to eggs, sperm and embryonic stem cells, 58 it only applies where these cells are 'intended for human application'. 59 As emphasised in recital 11, the 'Directive does not cover research using human tissues and cells'. It will, however, cover the creation of clinical grade embryonic stem cell lines where these are intended for human application at some future point. Third, the Directive does not define 'unpaid donation' except by declaring that it does not include compensation for the expenses and 'inconveniences' of the donation. This implies that the phrase 'as such' in the EU Charter is intended to be compatible with a distinction between impermissible 'payment' and permissible 'compensation' for inconvenience. Thus, the prohibition in Article 12 is only aspirational, does not apply to gamete donation for in vitro research, and does not encompass payment for the non-financial inconveniences of donation.
The Nuffield Council on Bioethics has drawn a distinction between 'recompense' (payment in recognition of losses incurred), 'reward' (material advantage that goes beyond 'recompensing' for incurred losses) and 'purchase' (payment in direct exchange for a 'thing'). 60 Article 12 apparently expresses opposition to both purchase and financial reward, while supporting recompense. The line between reward and recompense is not straightforward, because payments that may merely remove a disincentive to one person may provide an incentive to another.
Gamete-sharing schemes clearly do not involve the 'purchase' of gametes in the sense of direct exchange of money for the gametes themselves. Egg-sharing does not involve the transfer of money, but it does involve a 'payment' that has a clear cash value equivalent. Donation of eggs for treatment (but not in vitro research) through an egg-sharing arrangement would seem to involve a reward of the type rejected by Article 12. The issue is that there is no additional inconvenience for which to compensate the donor where she does not undergo any procedures beyond those required for her own treatment. Yet, if we point to the possibility that the donor could later need to undergo an additional egg-removal cycle due to the donation of eggs that she would otherwise have frozen for her own future treatment, then we must still face the fact that the reduction of fees operates in practice as a financial incentive, ie as reward rather than mere recompense. The HFEA's 2011 consultation concedes that 'most egg sharers would not donate if there were no incentive to do so'. 61 It is thus of significance that Article 12 lays down an aspiration rather than a strict requirement.
The rationale for Article 12 can be inferred from the Directive's recitals, which also provide guidance on its proper interpretation. Recital 18 asserts the principle that 'tissue and cell application programmes should be founded on the philosophy of voluntary and unpaid donation…., altruism of the donor and solidarity between donor and recipient'. Recital 19 apparently offers a justification of this principle: 'Voluntary and unpaid tissue and cell donations are a factor which may contribute to high safety standards for tissues and cells and therefore to the protection of human health. ' The view, expressed in recital 19, that paying for tissue and cell donations may threaten human health relates to the Directive's jurisdictional basis in Article 152(4)(a) of the EC Treaty (TEC), which has subsequently become Article 168(2)(4)(a) of the EU Treaty (TFEU). This provision provides for legislative competence to adopt 'measures setting high standards of quality and safety of organs and substances of human origin, blood and blood derivatives'. It also forms the jurisdictional basis of the earlier Blood Directive The link between (some forms of) payment and increased risk to human health-which is expressed rather tentatively in recital 19-was seminally suggested by the sociologist 60 Nuffield Council on Bioethics (n 7) para 2.44. Richard Titmuss in the context of blood donation in his book The Gift Relationship. 63 Titmuss cited evidence from the 1960s that suggested that recipients of blood sources from paid donors had higher rates of hepatitis than recipients who received blood from voluntary, unpaid donors. 64 This may be explainable on the basis that financial incentives attract different types of donors and they have an incentive to hide information about their health status that could lead to rejection and thus non-payment. As Farrell has pointed out, those in favour of financially rewarded blood donation reject the relevance of data from the 1960s and 1970s arguing that there are now 'stricter donor-screening protocols, more sophisticated testing and viral inactivation methods'. 65 Farrell goes on to analyse HIV/AIDS blood contamination episodes in the UK and France during the 1980s to highlight the inadequacy of what Titmuss referred to as the 'gift relationship' on its own for assessing risks to blood safety.
Applied to the donation of gametes, the concern would be that financially rewarded donors would be more likely to carry or hide transmissible infection or genetic disease. The major infections and genetic conditions should be caught by donor-screening protocols and blood tests, 66 but that still leaves the possibility of those that are unknown or not checked.
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There are a number of points to make about the adequacy of this claim as a justification for prohibiting the provision of incentives to gamete donors. While studies have demonstrated that the risk of disease transmission in blood donation is greater with paid donors than with unpaid donors, 68 there have been no studies demonstrating that paid gamete donation caries greater risk of transmitting genetic or infectious disease than gametes from unpaid donors.
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This perhaps explains why the risk to recipients was not cited by the HFEA to support its view that payment should be prohibited in its consultation in 2005. Even if such an increased risk could be established, its relevance would be restricted to donations of the type covered by the Directive, namely, those intended for human application. Infection cannot be transferred to a recipient and a child cannot be born with a genetic disorder where the material is only used for in vitro research. It would also seem to have little relevance to eggsharing arrangements, because patient donors will have been screened and tested for their own treatment over an extended period of time and be motivated to maximise their own chances of having a healthy child. In short, the effect of incentives on the quality of the gametes donated is only relevant to direct financial rewards for donation for treatment and even then such concerns are insufficient to justify a ban on incentives. A purposive reading of the Directive by reference to recital 19 and its jurisdictional basis would therefore support interpreting the requirement to endeavour to ensure unpaid (gamete) donation in terms of the possible health effects to the recipient of direct financial reward for donation for treatment or applied research.
Recital 18, which refers to the value of 'altruism' and 'solidarity between donor and recipient', suggests slightly wider purposes for the Directive. The Nuffield Council defines an altruistic action as 'one that is primarily motivated by concern for the welfare of the recipient of some beneficent behaviour, rather than by concern for the welfare of the person carrying out the action'. 70 It defines 'solidarity' as the idea that 'we're all in this together', which has 'an implication of mutual obligations and mutual support within a definable community'. 71 On these plausible definitions, egg-sharing may not be altruistic, but it remains consistent with solidarity because it 'reinforces the notion that many other couples are "in the same boat"'. 72 Overall, the Tissues and Cells Directive does not require the UK to prohibit the provision of incentives to gamete donors and its relevance is largely restricted to the provision of financial rewards to those who donate gametes for the treatment of others.
III. A NATIONAL SYSTEM AND INCENTIVISING POTENTIAL GAMETE DONORS
The case for allowing financial incentives for gamete donation has received detailed consideration in the academic literature 73 and in the policy documents of bodies such as the HFEA and the Nuffield Council on Bioethics. 74 Three analogies have particular force against the widespread assumption that a ban is ethically required: the analogy with risky employment (eg working on an oil-rig or in a deep mine or working as a professional boxer, racing car driver, or fire-fighter), the analogy with existing commercialisation (80% of IVF is private and, in the words of Robert Winston, 'IVF has become a massive commercial industry' 75 ), and the analogy with the paid participation of healthy volunteers in clinical trials of pharmaceutical products (volunteers in clinical trials are permitted to receive large payments, subject to conditions such as the approval of an ethics committee). 76 The risky employment analogy points out that other accepted paid activities carry significant risks or consequences and many give rise to no greater potential benefits, yet they are regulated rather than prohibited. The analogy with existing commercialisation points out that professionals who use donor gametes to treat or research are paid, often handsomely, for their services and the involuntarily childless now routinely pay large sums for access to assisted reproduction. The analogy with first-in-human trials points out that volunteer participants are 'overwhelmingly' motivated by the offer of financial reward. 77 Together these three analogies support a strong presumption in favour of providing a financial reward for the time, effort and inconvenience of gamete donation for both treatment and research, and they can be used to respond to many of the standard arguments against rewarding donors.
By way of example, consider the relevance of the risky employment and first-in-human trials analogies to the view expressed by the HFEA in its 1998 consultation that financial incentives are to be rejected on the basis that is 'possible' for a donor to be 'financially induced' and this 'might compromise the ability of the donor to consider fully the implications of the donation'. 78 work on an oil rig can suffer serious inconvenience, injury or even death and it is similarly 'possible' that they will have been 'financially induced' to participate, particularly those from disadvantaged backgrounds who have been subject to significant financial and social pressures. 79 The benefits of donation for the treatment of others or medical research are at least as compelling as the benefits associated with these other activities, especially with regard to professional sports. To respond by reference to the higher quality of consent that is generally required for consensual bodily interventions and procedures in a medical context runs into the healthy volunteer trials analogy, which demonstrates acceptance of procedural mechanisms beyond outright prohibition for ensuring voluntariness in a medical context.
The three analogies do have evident limitations; some of which are more significant than others. Since the purportedly analogous activities do not involve the purchase of persons or body parts, appeal to these analogies does not support the commodification (purchase) of gametes, 80 but these analogies do support the reward and recompense of donors. More significantly, these analogies do not fully address the concern that allowing financial incentives ultimately advantages the rich and powerful over the poor and vulnerable. It may be objected that the above analogies are satisfied by safeguards that are inadequate to ensure that proper account is taken of justice, equity and non-commercial research priorities. The risky employment analogy has nothing to say about those who can pay more than their competitors. The analogy with existing commercialisation reminds us that significant inequalities already exist; for example, those who can afford to attend the more expensive clinics or travel within and beyond the UK already have a greater range of opportunities than those reliant upon NHS-funded treatment. The analogy with healthy volunteer trials reminds us that referral to an ethics committee is one way to limit the magnification of inequalities, but perhaps more would be required to ensure that appropriate access to IVF treatment does not become even more expensive due to the cost of paying donors and that the priorities of embryo research are not left to large commercial entities. One way of addressing such issues is by putting control of payment and, most crucially of all, distribution of acquired gametes into the hands of a national non-profit body.
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The HFEA did not address financial incentives in its 2011 consultation, at least in part because it was operating on the assumption that the "law prohibits the payment of donors" 82 (on which see above). But we have seen that the latest policies of the HFEA do set fixed sum payments for those who donate (albeit payments tracking recompense rather than reward) and it is worth noting that others have expressed support for the idea of rewarding those who donate gametes for research (not least of which is the recent report of the Nuffield Council, which heavily relies on the analogy with healthy volunteer trials). 83 Nonetheless, support for a national donation system is much stronger than support for financial incentives and there are other types of incentives that are more likely to attract support. The rest of this article will therefore focus on the potential of a national gamete donation system to use the allocation of gametes to incentivise additional donations.
The existing system for the donation and allocation of bodily materials for transfusion and transplantation into patients is currently administered by NHS Blood and Transplant (NHSBT). This body operates in accordance with regulatory guidance set by other regulatory 79 As one of the reviewers has noted, employees in such risky environments have high level insurance cover and it maybe that introducing rewards for gametes would require increased insurance cover. Nuffield Council on Bioethics (n 7) esp paras 6.74 and 6.81. bodies, including the Human Tissue Authority (HTA)-a body that is to have the same fate as the HFEA. 84 NHSBT has been relatively successful in controlling supply and demand for blood. Blood shortages in the UK are now rare, 85 although blood supplies remain under constant pressure and there have been seasonal shortages of some blood groups. 86 One reason for the constant pressure is that donors represent a tiny minority of potential donors: according to NHSBT, '96% of us rely on the other 4% to give blood'. 87 The problem is far worse for the supply of solid organs, where shortages mean that hundreds of patients die each year from organ failure while waiting for a transplant. 88 NHSBT has adopted detailed procedures to ensure that organs donated for transplantation are fairly and appropriately matched and allocated to patients. 89 Patients waiting for transplants are registered on the National Transplant Database and a computer programme is used to identify the best matched patients (taking account of factors such as blood group, age, and size of both the donor and recipient) or, alternatively, the transplant unit to which the organ is to be offered. The relevant criteria are 'determined by the medical profession in consultation with other health professionals, the Department of Health and specialist advisory groups'. 90 The resulting allocation algorithms are complex and vary according to the type of organ. In complex cases patients are prioritised according to a point score, whereby organs are allocated to the patients with the highest number of points. Points are allocated for factors such as time on the waiting list, tissue match, age difference between donor and patient, location of the patient relative to the donor, etc. NHSBT assessment and allocation policies have not gone without academic criticism, 91 but generally seem to operate fairly. If the UK were to extend the remit of the NHSBT (or set up an equivalent body) to administer gamete acquisition and allocation, it could remove the significant regional variations and inequalities of access that currently beset the use of donor gametes in fertility treatment and it could enable centralised support for research uses of gametes. The considerations of justice, transparency and equality that apply to organ donation for transplantation have equivalent relevance to gamete donation. The adoption of a points-based system for the allocation of gametes for treatment would similarly enable a range of factors to be properly balanced in the just distribution of this scarce resource.
Identifying and weighing the relevant factors for gamete donation can only use the organ donation system as a model if the differences between the two types of donation are recognised. The two systems have different goals: organs donated for transplantation are used to replace the functions of failing organs, whereas gametes donated for fertility treatment are 84 As a result of the Human Tissue Act 2004, the HTA is currently responsible for regulating the removal, storage and use of tissue (other gametes and embryos) for research, medical treatment, post-mortem examination, teaching and public display. used to address involuntary childlessness. 92 It follows that whereas the relative medical urgency of a transplant can be measured in terms of the predicted time until organ failure, the relative medical urgency of fertility treatment would need to track the predicted time left for which pregnancy is a realistic and appropriately safe prospect. 93 Time on the waiting list raises the same considerations of justice and equity and can be identified in the same way for both systems. In the case of gamete donation, it may also be appropriate to give weight to the need for gametes to avoid the transmission of serious genetic disease, since this can be identified by medical criteria, is already regarded as a relevant factor by the 1990 Act, 94 and generally has a wider impact on healthcare resources. One way of doing this would be grant those who require gametes to avoid the transmission of a genetic disease points corresponding to something like the number of points obtained after the mean waiting time. 95 The organ allocation system thus provides a model for some aspects of a gamete allocation system but not all. We have seen that the organ allocation system has a procedure for reviewing and establishing the specific weight given to the factors identified as relevant, a similar procedure is required for gamete allocation if it is to be made transparent and removed from the unregulated discretion of individual clinics.
At present, prospective parents select individual donors on the basis of their traits, such as matching physical characteristics and ethnic background. If we continue to accept this practice (and such selection is controversial), 96 the larger pool of gametes held by a national system should facilitate such choices. The allocation system could take account of patientspecified matching criteria, whereby the gametes of donors who have certain characteristics are allocated only to those who have specified those characteristics or have chosen not to express any such preference.
The national coordination of gamete donation would also enable the implementation of other methods of encouraging gamete donation, which will be explored below.
A. Mirror Exchange
An additional feature of the national system for managing organ donations from living donors for transplantation is that it admits a type of non-financial incentive. It allows 'mirror exchange', whereby recipient X recruits a donor to supply an organ in exchange for an organ supplied by someone recruited by recipient Y. Two types of mirror organ exchange programme are currently administered by NHSBT. The first is 'paired donation'. Imagine that Arthur needs a kidney transplant and has a willing donor but that donor is not a suitable tissue match. If Bella is in the same position she could receive the kidney from Arthur's donor and Arthur would receive the kidney from Bella's donor. Alternatively, there is 'pooled donation'. Imagine that Bella's donor is not a tissue match for Arthur, and Celia also needs a kidney and has a willing donor who is not a match to her. It is possible to arrange a chain of paired donations if Arthur's donor is a match for Celia's donor and Celia is a match for Bella's donor.
Since the current gamete donation system permits the donation of gametes to someone you know or a stranger and the organ allocation system permits paired and pooled donation, few ethical issues should be raised by putting the two together to provide for the paired and pooled donation of gametes. The Tissues and Cells Directive applies equally to both activities and paired/pooled donation is explicitly approved by the legalisation governing transplantation. 97 Indeed, if we accept that rewarded egg-sharing is consistent with the values of altruism and solidarity, as evoked by the Tissues and Cells Directive, then it is difficult to avoid the conclusion that a mirror system for gamete donation is also to be regarded as compatible with those values.
Applied to gametes, it would usually be the partner of the infertile person who provides the donor contribution. Like paired and pooled organ donation, this need not be the case. The donor could be someone else close to the person in need who is willing to help but unable to donate directly to that person. In the case of gamete donation, the inability to donate directly to the person in need could stem from the impermissibility of mixing the gametes of close genetic relatives. 98 A sister is not, for example, able to donate eggs directly to her brother so that he can have children with his partner, but she would be able to donate in a mirror exchange system to enable her brother to receive an egg from another donor. With gametes, unlike organs, the donor could even be the person who wishes to receive donor gametes from another. A single woman would be able to donate her own eggs in exchange for the sperm of a man whose female partner is infertile. It is difficult to predict the extent to which a mirror exchange system modelled on that applying to organs would increase the supply of gametes for treatment, but these hypothetical examples suggest it could be attractive to at least some of those who would not otherwise donate. Mirror exchange has already been shown to be successful for organs: in the last year 'paired and pooled donations contributed more than 60 kidney transplants between them'. 99 The two examples just presented also highlight the relevance of altruism (the first example) and solidarity (particularly the second example) to gamete mirror exchange.
Unlike organ donation, where both pairs donate and receive the same organ, the donor in one pair will often be shouldering more of a burden than the donor in the exchange couple. Sperm donation involves a series of appointments for health screening and blood and semen tests, but the donation itself is not invasive. 100 Whereas egg donation involves hormonal medication, ultrasound scanning, and a surgical procedure to remove the eggs; and this process carries the risk of complications, such ovarian hyperstimulation syndrome (OHSS).
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In short, egg donation is more invasive and risky than sperm donation. One possible response would be for the mirror exchange programme to adopt the approach taken in egg-sharing arrangements, whereby egg donation is restricted to situations where the woman is already having eggs removed for her own IVF treatment. 102 But such a response is likely to create or The HFEA has decided to adopt an explicit ban this practice, even though there are no known cases of UK clinics mixing the gametes of close genetic relatives: HFEA, 'HFEA agrees new policies about family donation and the number of families one donor can create' Press Release, 14 July 2011.
Imagine, instead, a lesbian couple where both women have healthy eggs but are too old to be accepted as egg donors for another's fertility treatment. 111 If they are willing to contribute blood for the next two years in exchange for quicker access to donor sperm, they could be told that they may obtain a set number of bonus points to improve their waiting list ranking by committing to one of the recognised donation schemes. Blood transfusions can be lifesaving and blood supplies are under constant pressure, yet blood donation is a relatively simple process and raises far fewer issues for the donor compared to gamete donation. On the face of it, there seems to be no reason why rewarding contributions in a points-based system could not also reward previous and prospective blood donations from the person or couple who are to receive treatment. The level of points granted for blood donation compared to gamete donation would need to be set periodically in accordance with supply and demand. I have deliberately chosen blood donation as the example because the case for rewarding blood donation to increase supply is much weaker than the case for rewarding donations of solid organs.
There are at least two plausible objections to extending indirect mirror exchange beyond donor contributions of gametes.
The first plausible objection is that there is already a prima facie ethical obligation to donate blood, unlike gametes, and it is inappropriate to reward people for doing what they already have an obligation to do. There are good reasons to accept the first part of this claim. The conditions for the imposition of moral duties to assist those in need have been fully explored in the literature. 112 These are: (1) the assistance must be required to protect another's important interests; (2) the person on whom the burden of assistance falls must be in a position to assist; (3) the assistance must not impose an unreasonable burden; and (4) the persons requiring assistance must not be in a position to self-assist. Blood donation required for life-saving transfusion generally satisfies those conditions, because it is clearly needed to protect another's important interests, you know or ought to know that this is so, providing blood does not usually impose an unreasonable burden on you relative to the life of those in need of blood, and those in need of an blood transfusion are usually in no position to assist themselves. In contrast, gamete donation (like organ donation) generally involves a disproportionate burden on the assister. Gamete donation is likely to engage deep social and moral beliefs, because embryo research involves the destruction of an entity that could develop into a human person and donated gametes used for fertility treatment are intended to create a biological child who will be able to obtain identifying information about the donor at the age of 18. Egg donation also requires drug-induced stimulation of the ovaries and invasive surgery with attended risks to health and even life. Thus, there is indeed already a prima facie obligation to donate blood but not such an obligation to donate gametes.
The second part of the first plausible objection is less convincing because the existence of a duty to assist does not imply the impermissibility of seeking to motivate people to act in accordance with their moral obligations. The law does not generally enforce duties to assist individuals 113 and does not generally require individuals to assist the achievement of social goods, save through taxation. One exception to the latter is jury participation, which the HFEA previously used analogically to set the maximum daily compensation level for gamete donation. 114 Jury service is necessary for the maintenance of a criminal justice system of the type adopted in the UK and can place considerable burdens on jurors in relation to freedom of speech and physical liberty during a trial. 115 These burdens do not, however, involve the physical invasion of one's body, are less likely to give rise to legitimate conscientious objection and can be legally enforced in an ethically appropriate and proportionate manner. Thus, rewarding compliance with positive duties to donate blood is generally preferable to legally enforcing such duties.
The second plausible objection to extending points-based allocation to encompass donor contributions of blood is that such an action would be counterproductive because it would negatively affect blood donation rates and threaten the motivational effect of altruism and solidarity within the current blood donation system. A similar objection to this was made by Titmuss, who argued that allowing payment for blood donation would negatively affect the 'gift relationship', 116 in the sense that payment would discourage altruistic donation and weaken the persuasive force of the argument of solidarity. Of course, Titmuss did not himself consider benefits-in-kind of the kind adopted in an indirect mirror exchange system and there is no empirical research on this matter. Such an objection could therefore not support the blanket exclusion of rewarding blood and solid organ contributions in an indirect mirror exchange system, rather it points to the need to pilot the system first.
Any new gamete allocation system will need to be piloted before being adopted. The idea that rewarding donor contributions when allocating gametes could increase the supply of gametes is supported by the trial of a less ambitious system. 117 The present proposal is more ambitious because it envisages a system of gamete allocation that takes account of gamete donations for treatment, gamete donations for research and even donations of other bodily materials for transfusion and transplantation. Such a system is likely to fail to motivate additional donations if those in need of gametes are not incentivised by what they expect to get in return for their contribution, and this will require carefully piloting and monitoring. That is not to suggest that the ethical justification for indirect mirror exchange is coterminous with its predicted success at increasing donor contributions. At least parts of its justification stems from the view that it is fair and appropriate to take account of the willingness to donate bodily material when allocating gametes, and this is supported by the principle of solidarity.
C. Returning a Donation to the Allocation Pool
Creating embryos outside the body for assisted reproduction can result in the creation of more embryos than are immediately implanted into a woman's body-sometimes referred to as 'spare' or 'surplus' embryos. At present, such embryos created using a donor egg or sperm may be frozen and kept within the statutory storage period 118 as long as neither gamete provider withdraws consent. Many of these stored embryos will be discarded months or years later when those receiving treatment decide that they have no more use for them or the statutory storage period expires. Donation to another woman or couple is a possibility but not a requirement. This is so even though destruction is likely to frustrate the intentions of the gamete donor and even though embryos are needed for treatment and research. This is worth considering in the context of a hypothetical national donation system, because such a system could operate to reduce the loss of these embryos by allocating additional points to those who agree to donate any resultant embryos that they do not use within a set period of time. It is even possible to link the points to the storage period, so that a couple wanting to, say, create an embryo using donor sperm could get points for agreeing that any unimplanted embryos are donated after ten years and additional points for agreeing to donation after only five years. Such a system would not lead to women implanting problematic numbers of embryos to ensure that none remained for storage because the HFEA already severely restricts the number that may be implanted at any one time.
119
Would this, however, effectively coerce those seeking access to donor reproductive material into donating their own material or rushing subsequent decisions on whether to use the stored embryos themselves? This question carries two concerns. The first has been overstated, because the proposed system is not making donation compulsory, rather it is providing a slight incentive to those who agree to donation in advance. Those seeking access to donation cannot coherently object to donation in principle and, indeed, the principle of solidarity (and, in the case of blood, general positive duties) supports a prima facie obligation to donate. With regard to the second concern, it should be borne in mind that the law already takes the view that the option of using frozen embryos should not be kept open indefinitely, as shown by the existence of the statutory storage period. Nonetheless, any such system would need to be able to take account of genuine reasons (eg illness) for later extending the storage period.
V. CONCLUSION
This article has examined the potential role that a national donation system could play in the legal and ethical implementation of incentives to gamete donation. It argues that a national donation system could enable the implementation of an ethically defensible mirror exchange system, but a preferable way to incentivise gamete donation for both treatment and research would be through a system of indirect mirror exchange. Such a system would enable the allocation of gametes to track factors such as medical urgency, waiting time and (perhaps) avoidance of transmission genetic disease, while also rewarding donor contributions. An indirect mirror exchange system of this type could operate alongside or instead of an ethically implemented system of payment of donors.
